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Research carried out in the 1940’s gave some of our first inklings of the pharmacological 
potential of chemicals extracted from Cannabis sativa (Loewe & Adams, 1947), but it was 
not until the early 1960’s that Δ9-tetrahyrocannabinol (Δ9-THC) was shown to be one of the 
major constituents of cannabis that induces behavioural and psychoactive changes (Boyd et 
al., 1963).  The next 30 years led to intensive research around the pharmacology of Δ9-THC 
and other related plant-derived cannabinoids that, over time, led to the discovery and 
subsequent identification in the early 1990’s of (i) G-protein-coupled CB1 (Matsuda et al., 
1990) and CB2 (Munro et al., 1993) cannabinoid receptors, (ii) endogenous CB receptor 
ligands, of which N-arachidonoyl-ethanolamine (anandamide; AEA; Devane et al., 1992) and 
2-arachidonyl glycerol (2-AG; Mechoulam et al., 1995) represent the most intensively 
studied, and (iii) the associated enzymatic apparatus which controls their synthesis and 
degradation (recently reviewed by Cascio & Marini, 2015).  Taken together these three 
components were subsequently described as the endocannabinoid system (ECS), which has 
since been shown to comprise an endogenous signalling system that plays a pivotal role in a 
variety of centrally and peripherally regulated physiological processes, including pain 
sensation, appetite, memory, mood and inflammation, and in the pathophysiology of 
numerous disease states including cancer, diabetes, obesity and cardiovascular disease.  To 
date in excess of 7,000 original articles and reviews have been published (>300 in the British 
Journal of Pharmacology) that have helped advance our knowledge about this complex and 
intriguing system.  In this virtual themed issue of the BJP a further review and three original 
papers add additional insight and understanding of the role of the ECS in diabetes (and its 
complications; Gruden et al., 2015), obesity-related nephropathy (Jenkin et al., 2015) and 
drug withdrawal (Wang et al., 2014).  Additionally Petrosino’s paper (Petrosino et al., 2015) 
describes the intricate interaction between various elements of the ECS and their cellular 
targets. 
Type 2 diabetes has been described as a pandemic, and the global incidence is persistently 
on the rise due to growing levels of obesity.  The catastrophic consequences that follow the 
development of this condition, in the form of complications such as diabetic retinopathy, 
nephropathy, neuropathy and cardiovascular disease, only serves to heighten the need for 
effective treatments to both prevent and manage the disease.  The ECS has been known for 
some time to play an important regulatory central role in food intake, however it is only in 
the last 10-15 years that we have come to appreciate an equally important role in peripheral 
tissues that contribute to energy metabolism and homeostasis, such as adipose tissue and 
pancreatic islets (reviewed by Silvestri and DiMarzo, 2013).  In this themed issue of the BJP, 
an excellent review from Pal Pacher’s group provides an update on the role of the ECS in 
obesity and insulin resistance, alongside a detailed description of how the peripheral ECS is 
important in the pathogenesis of diabetic nephropathy, neuropathy and cardiomyopathy 
(Gruden et al., 2015).  In this review they highlight the opposing effects of the two 
cannabinoid (CB1 and CB2) receptors in various cellular events implicated in the development 
of diabetic complications, including inflammation and oxidative stress, where activation of 
CB2 or blockade of CB1 both present potential opportunities for drug development in the 
treatment of diabetic complications.  However the review also emphasises the challenges 
faced in terms of the selectivity of agents for each of the CB receptors and their centrally-
mediated adverse effects, the latter requiring the development of peripherally restricted 
cannabinoid-based therapies.  Of particular interest is the apparent association between a 
common polymorphism in the CB1 receptor and the occurrence of nephropathy and 
retinopathy in Type 2 diabetics; although the functional importance of these remains to be 
demonstrated, this may provide a promising approach to the management of complications 
of this disorder.   
Aligning well with the above review, also within this issue is an original contribution from 
Jenkin et al (2015) that focuses on the role of CB2 in obesity-induced renal dysfunction.  
Using a high fat diet-induced rat model of obesity, they studied the effects of both activation 
(with AM1241) and blockade (with AM630) of the CB2 receptor.  While neither compound 
influenced weight gain, AM1241 markedly improved a number of renal function markers, 
while AM630 led to a worsening of the renal dysfunction, adding to the existing body of 
evidence that CB2 receptor activation may be of benefit in obesity-related nephropathy.  
However, as noted in Gruden’s review, the potential adverse effects on insulin resistance 
that have been reported  following CB2 receptor activation, albeit with a different CB2 
agonist (JH-133; Deveaux et al., 2009) underlines the need for the development of ligands 
that are highly selective for the CB receptor target. 
Inflammation is one of the key events that contribute to the development of diabetic 
complications.  To date the focus on the role of the ECS in the inflammatory process has 
been on the two most studied EC’s anandamide (AEA) and 2-arachidonyl glycerol (2-AG).  In 
the paper by Petrosino et al., (2015) we are reminded that other products of the same 
synthetic pathways that give rise to AEA play an important role in EC signalling.  
Palmitoylethanolamide (PAE) is an AEA congener that is synthesised alongside AEA, and 
various reports from the literature show that it can modulate the action of AEA at both CB 
receptors.  Moreover, this article similarly reminds us that AEA has actions not only at the G-
protein coupled receptors, but also at other cellular targets, including TRPV1, while on the 
other hand 2-AG is relatively inactive at the CB receptors yet a “physiologically relevant” 
activator of TRPV1.  Here Petrosino et al describe studies to demonstrate that, while PEA 
itself has very low affinity for both CB receptors and TRPV1, it appears to play an important 
role in modulating the activity of 2-AG at this receptor (so called pleiotropic effects).  Using a 
combined in vivo and in vitro approach, PEA was found to elevate 2-AG levels in cultured 
keratinocytes and to raise plasma levels of 2-AG following oral administration in both 
humans and dogs.  However at the cellular level, PEA only slightly augmented the activation 
of TRPV1 by 2-AG while increasing the 2-AG-induced desensitisation of TRPV1 to capsaicin.  
Through these experiments the authors have extended the previously described “entourage 
effect” of PEA on AEA signalling (De Petrocellis et al., 2001) to that for 2-AG, providing a 
plausible explanation for why antagonists of both CB receptors and TRPV1 attenuate 
responses to PEA. 
Moving away from the topic of diabetes and obesity, the final paper in this themed issue 
tackles the subject of the involvement of the ECS in pathways that regulate drug addition.  
CB1 receptors are highly expressed in regions of the brain linked with reward and drug 
addiction, and CB1 activation has been shown to re-instate drug-seeking behaviour, while 
CB1 blockade has the opposite effect.  Previous evidence has suggested that synaptic 
plasticity occurs as both a short and long-term event in various areas of the brain associated 
with drug reward and addiction.  Wang et al., (2014) have studied the role of the ECS in 
synaptic plasticity within the nucleus accumbens, where they have provided important 
evidence to show that the modulation of inhibitory synaptic transmission by 
endocannabinoids is magnified following short-term morphine withdrawal in rats.  In the 
case of 2-AG, but not AEA, this was associated with an increased expression, of 
diacylglycerol lipase α (DAGLα), which is the enzyme responsible for 2-AG synthesis; 
although the precise mechanism underlying this remains to be identified, the findings of this 
study emphasise once more not only the complexity of the roles that the ECS plays in 
physiology (and pathophysiology), but also that the ECS is under exquisite control by both 
itself and other systems. 
Despite the growing understanding of the ECS, one theme that emerges from all of the 
papers in this issue is that we need to know more about how the ECS works in order to be 
able to develop novel drugs targeting the this system.  In particular we need to understand 
how the ECS “self regulates”, so that, when one pathway or receptor is blocked, we avoid 
activating a different pathway that would either negate what we are trying to achieve, or 
trigger adverse effects.  Although advances are being made in the development of novel 
agents targeting only peripheral CB1 receptors (to avoid the adverse psychiatric effects seen 
with centrally acting CB1 antagonists) we still need to be cautious about how blockade of 
these receptors may impact upon the fine balance within the ECS that is helping to maintain 
physiological control, particularly in body systems that are unrelated to the target system.  
Drug selectivity is also key, since very few cannabinoid ligands (acting as either agonists or 
antagonists) appear to be completely selective for one receptor, reflecting in a way the 
promiscuity of the endogenous cannabinoid ligands themselves.  Finally the behaviour of 
cannabinoid ligands at different receptors may vary depending upon whether or not they 
are being studied in cell systems, tissue preparations or in vivo; indeed, at least in terms of 
haemodynamic responses, recent data shows that the receptor activity profile of “selective” 
cannabinoid ligands can vary between in vitro and in vivo model systems (Walsh et al., 2015) 
which may reflect an involvement of the ECS and receptor cross-talk in intact animals that is 
not observed in isolated cells.  There is therefore a strong possibility that such discrepancies 
may also be seen in other physiological systems.   
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